• Something wrong with this record ?

Prenatal MAM exposure raises kynurenic acid levels in the prefrontal cortex of adult rats

F. Frescura, T. Stark, E. Tiziani, S. Di Martino, J. Ruda-Kucerova, F. Drago, L. Ferraro, V. Micale, S. Beggiato

. 2024 ; 76 (4) : 887-894. [pub] 20240524

Language English Country Switzerland

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc24019571

Grant support
Project no. PE00000006 Partnership for Research and Innovation in the Mediterranean Area
2023 FAR2023

BACKGROUND: Elevated brain levels of kynurenic acid (KYNA), a metabolite in the kynurenine pathway, are associated with cognitive dysfunctions, which are nowadays often considered as fundamental characteristics of several psychopathologies; however, the role of KYNA in mental illnesses, such as schizophrenia, is not fully elucidated. This study aimed to assess KYNA levels in the prefrontal cortex (PFC) of rats prenatally treated with methylazoxymethanol (MAM) acetate, i.e., a well-validated neurodevelopmental animal model of schizophrenia. The effects of an early pharmacological modulation of the endogenous cannabinoid system were also evaluated. METHODS: Pregnant Sprague-Dawley rats were treated with MAM (22 mg/kg, ip) or its vehicle at gestational day 17. Male offspring were treated with the cannabinoid CB1 receptor antagonist/inverse agonist AM251 (0.5 mg/kg/day, ip) or with the typical antipsychotic haloperidol (0.6 mg/kg/day, ip) from postnatal day (PND) 19 to PND39. The locomotor activity and cognitive performance were assessed in the novel object recognition test and the open field test in adulthood. KYNA levels in the PFC of prenatally MAM-treated rats were also assessed. RESULTS: A significant cognitive impairment was observed in prenatally MAM-treated rats (p < 0.01), which was associated with enhanced PFC KYNA levels (p < 0.05). The peripubertal AM251, but not haloperidol, treatment ameliorated the cognitive deficit (p < 0.05), by normalizing the PFC KYNA content in MAM rats. CONCLUSIONS: The present findings suggest that the cognitive deficit observed in MAM rats may be related to enhanced PFC KYNA levels which could be, in turn, mediated by the activation of cannabinoid CB1 receptor. These results further support the modulation of brain KYNA levels as a potential therapeutic strategy to ameliorate the cognitive dysfunctions in schizophrenia.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24019571
003      
CZ-PrNML
005      
20241024110626.0
007      
ta
008      
241015s2024 sz f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s43440-024-00604-6 $2 doi
035    __
$a (PubMed)38789891
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Frescura, Francesca $u Department of Life Sciences and Biotechnology, University of Ferrara, Via L. Borsari 46, 44121, Ferrara, Italy
245    10
$a Prenatal MAM exposure raises kynurenic acid levels in the prefrontal cortex of adult rats / $c F. Frescura, T. Stark, E. Tiziani, S. Di Martino, J. Ruda-Kucerova, F. Drago, L. Ferraro, V. Micale, S. Beggiato
520    9_
$a BACKGROUND: Elevated brain levels of kynurenic acid (KYNA), a metabolite in the kynurenine pathway, are associated with cognitive dysfunctions, which are nowadays often considered as fundamental characteristics of several psychopathologies; however, the role of KYNA in mental illnesses, such as schizophrenia, is not fully elucidated. This study aimed to assess KYNA levels in the prefrontal cortex (PFC) of rats prenatally treated with methylazoxymethanol (MAM) acetate, i.e., a well-validated neurodevelopmental animal model of schizophrenia. The effects of an early pharmacological modulation of the endogenous cannabinoid system were also evaluated. METHODS: Pregnant Sprague-Dawley rats were treated with MAM (22 mg/kg, ip) or its vehicle at gestational day 17. Male offspring were treated with the cannabinoid CB1 receptor antagonist/inverse agonist AM251 (0.5 mg/kg/day, ip) or with the typical antipsychotic haloperidol (0.6 mg/kg/day, ip) from postnatal day (PND) 19 to PND39. The locomotor activity and cognitive performance were assessed in the novel object recognition test and the open field test in adulthood. KYNA levels in the PFC of prenatally MAM-treated rats were also assessed. RESULTS: A significant cognitive impairment was observed in prenatally MAM-treated rats (p < 0.01), which was associated with enhanced PFC KYNA levels (p < 0.05). The peripubertal AM251, but not haloperidol, treatment ameliorated the cognitive deficit (p < 0.05), by normalizing the PFC KYNA content in MAM rats. CONCLUSIONS: The present findings suggest that the cognitive deficit observed in MAM rats may be related to enhanced PFC KYNA levels which could be, in turn, mediated by the activation of cannabinoid CB1 receptor. These results further support the modulation of brain KYNA levels as a potential therapeutic strategy to ameliorate the cognitive dysfunctions in schizophrenia.
650    _2
$a zvířata $7 D000818
650    12
$a prefrontální mozková kůra $x metabolismus $x účinky léků $7 D017397
650    _2
$a těhotenství $7 D011247
650    _2
$a ženské pohlaví $7 D005260
650    12
$a zpožděný efekt prenatální expozice $x metabolismus $7 D011297
650    12
$a kyselina kynurenová $x metabolismus $7 D007736
650    12
$a potkani Sprague-Dawley $7 D017207
650    _2
$a krysa rodu Rattus $7 D051381
650    _2
$a mužské pohlaví $7 D008297
650    12
$a schizofrenie $x metabolismus $x farmakoterapie $7 D012559
650    12
$a methylazoxymethanolacetát $x analogy a deriváty $7 D008746
650    _2
$a haloperidol $x farmakologie $7 D006220
650    _2
$a piperidiny $x farmakologie $7 D010880
650    _2
$a modely nemocí na zvířatech $7 D004195
650    _2
$a antipsychotika $x farmakologie $7 D014150
650    _2
$a pyrazoly $x farmakologie $7 D011720
650    _2
$a kognitivní dysfunkce $x metabolismus $x farmakoterapie $7 D060825
650    _2
$a receptor kanabinoidní CB1 $x metabolismus $7 D043884
655    _2
$a časopisecké články $7 D016428
700    1_
$a Stark, Tibor $u Department Emotion Research, Max Planck Institute of Psychiatry, 80807, Munich, Germany
700    1_
$a Tiziani, Edoardo $u Department of Life Sciences and Biotechnology, University of Ferrara, Via L. Borsari 46, 44121, Ferrara, Italy $1 https://orcid.org/0000000293030561
700    1_
$a Di Martino, Serena $u Department of Biomedical and Biotechnological Sciences, University of Catania, 95123, Catania, Italy
700    1_
$a Ruda-Kucerova, Jana $u Department of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czech Republic $1 https://orcid.org/0000000218460799 $7 xx0068341
700    1_
$a Drago, Filippo $u Department of Biomedical and Biotechnological Sciences, University of Catania, 95123, Catania, Italy $1 https://orcid.org/0000000328875223
700    1_
$a Ferraro, Luca $u Department of Life Sciences and Biotechnology, University of Ferrara, Via L. Borsari 46, 44121, Ferrara, Italy. luca.ferraro@unife.it $u LTTA Centre, University of Ferrara, Ferrara, Italy. luca.ferraro@unife.it $u Psychiatric Department, School of Medicine, University of Maryland, Baltimore, MD, USA. luca.ferraro@unife.it $1 https://orcid.org/0000000323906414
700    1_
$a Micale, Vincenzo $u Department of Biomedical and Biotechnological Sciences, University of Catania, 95123, Catania, Italy $1 https://orcid.org/0000000262328859
700    1_
$a Beggiato, Sarah $u Department of Life Sciences and Biotechnology, University of Ferrara, Via L. Borsari 46, 44121, Ferrara, Italy $u Psychiatric Department, School of Medicine, University of Maryland, Baltimore, MD, USA $1 https://orcid.org/0000000288267556
773    0_
$w MED00165879 $t Pharmacological reports : PR $x 2299-5684 $g Roč. 76, č. 4 (2024), s. 887-894
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38789891 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20241015 $b ABA008
991    __
$a 20241024110620 $b ABA008
999    __
$a ok $b bmc $g 2202041 $s 1231544
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 76 $c 4 $d 887-894 $e 20240524 $i 2299-5684 $m Pharmacological reports : PR $n Pharmacol Rep $x MED00165879
GRA    __
$a Project no. PE00000006 $p Partnership for Research and Innovation in the Mediterranean Area
GRA    __
$a 2023 $p FAR2023
LZP    __
$a Pubmed-20241015

Find record

Citation metrics

Archiving options